England-based Microbiotica has raised $67 million in a series B round to push two microbiome-based lead assets through phase 1b trials, slated to start this year. The company launched in 2016 to develop bacterial therapies and biomarkers utilizing the human microbiome, which is a source of trillions of microorganisms that exist in the body. The company was founded with GBP 8 million ($10.4 million) in initial funding. Source: Fierce Biotech 7/3/22